Alector Inc
NASDAQ:ALEC

Watchlist Manager
Alector Inc Logo
Alector Inc
NASDAQ:ALEC
Watchlist
Price: 5.06 USD -1.27% Market Closed
Market Cap: 492.4m USD
Have any thoughts about
Alector Inc?
Write Note

Intrinsic Value

ALEC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ALEC stock under the Base Case scenario is 6.06 USD. Compared to the current market price of 5.06 USD, Alector Inc is Undervalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALEC Intrinsic Value
6.06 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Alector Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ALEC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ALEC?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Alector Inc

Provide an overview of the primary business activities
of Alector Inc.

What unique competitive advantages
does Alector Inc hold over its rivals?

What risks and challenges
does Alector Inc face in the near future?

Summarize the latest earnings call
of Alector Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Alector Inc.

Provide P/S
for Alector Inc.

Provide P/E
for Alector Inc.

Provide P/OCF
for Alector Inc.

Provide P/FCFE
for Alector Inc.

Provide P/B
for Alector Inc.

Provide EV/S
for Alector Inc.

Provide EV/GP
for Alector Inc.

Provide EV/EBITDA
for Alector Inc.

Provide EV/EBIT
for Alector Inc.

Provide EV/OCF
for Alector Inc.

Provide EV/FCFF
for Alector Inc.

Provide EV/IC
for Alector Inc.

Show me price targets
for Alector Inc made by professional analysts.

What are the Revenue projections
for Alector Inc?

How accurate were the past Revenue estimates
for Alector Inc?

What are the Net Income projections
for Alector Inc?

How accurate were the past Net Income estimates
for Alector Inc?

What are the EPS projections
for Alector Inc?

How accurate were the past EPS estimates
for Alector Inc?

What are the EBIT projections
for Alector Inc?

How accurate were the past EBIT estimates
for Alector Inc?

Compare the revenue forecasts
for Alector Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Alector Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Alector Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Alector Inc compared to its peers.

Compare the P/E ratios
of Alector Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Alector Inc with its peers.

Analyze the financial leverage
of Alector Inc compared to its main competitors.

Show all profitability ratios
for Alector Inc.

Provide ROE
for Alector Inc.

Provide ROA
for Alector Inc.

Provide ROIC
for Alector Inc.

Provide ROCE
for Alector Inc.

Provide Gross Margin
for Alector Inc.

Provide Operating Margin
for Alector Inc.

Provide Net Margin
for Alector Inc.

Provide FCF Margin
for Alector Inc.

Show all solvency ratios
for Alector Inc.

Provide D/E Ratio
for Alector Inc.

Provide D/A Ratio
for Alector Inc.

Provide Interest Coverage Ratio
for Alector Inc.

Provide Altman Z-Score Ratio
for Alector Inc.

Provide Quick Ratio
for Alector Inc.

Provide Current Ratio
for Alector Inc.

Provide Cash Ratio
for Alector Inc.

What is the historical Revenue growth
over the last 5 years for Alector Inc?

What is the historical Net Income growth
over the last 5 years for Alector Inc?

What is the current Free Cash Flow
of Alector Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Alector Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Alector Inc

Current Assets 469.4m
Cash & Short-Term Investments 457.2m
Other Current Assets 12.2m
Non-Current Assets 46.7m
PP&E 39m
Other Non-Current Assets 7.6m
Current Liabilities 142.5m
Accounts Payable 5m
Accrued Liabilities 37.8m
Other Current Liabilities 99.8m
Non-Current Liabilities 254.6m
Other Non-Current Liabilities 254.6m
Efficiency

Earnings Waterfall
Alector Inc

Revenue
61.5m USD
Operating Expenses
-244.5m USD
Operating Income
-183m USD
Other Expenses
24.6m USD
Net Income
-158.4m USD

Free Cash Flow Analysis
Alector Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Alector is set for transformative advancements with anticipated key trial readouts. The AL002 Phase II trial for early Alzheimer’s disease will deliver data in Q4 2024, focusing on its TREM2 agonist. Additionally, the FDA has granted breakthrough therapy designation to latozinemab for frontotemporal dementia, with a pivotal Phase III readout expected in late 2025 or early 2026. Financially, Alector ended the quarter with $503.3 million in cash, ensuring operations through 2026. The company also projects collaboration revenue between $60 million and $70 million for 2024. Its proprietary Alector Brain Carrier platform continues to enhance drug delivery capabilities.

What is Earnings Call?
Fundamental Scores

ALEC Profitability Score
Profitability Due Diligence

Alector Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
9/100
Profitability
Score

Alector Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

ALEC Solvency Score
Solvency Due Diligence

Alector Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Alector Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALEC Price Targets Summary
Alector Inc

Wall Street analysts forecast ALEC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALEC is 14.03 USD with a low forecast of 4.04 USD and a high forecast of 36.75 USD.

Lowest
Price Target
4.04 USD
20% Downside
Average
Price Target
14.03 USD
177% Upside
Highest
Price Target
36.75 USD
626% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ALEC?

Click here to dive deeper.

Dividends

Alector Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALEC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Alector Inc Logo
Alector Inc

Country

United States of America

Industry

Biotechnology

Market Cap

495.5m USD

Dividend Yield

0%

Description

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

Contact

CALIFORNIA
South San Francisco
131 Oyster Point Blvd., Suite 600
+14152315660.0
alector.com

IPO

2019-02-07

Employees

208

Officers

Co-Founder, CEO & Director
Dr. Arnon Rosenthal Ph.D.
President and Head of Research & Development
Dr. Saraswati Kenkare-Mitra Ph.D.
CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Marc Grasso M.D.
Chief Medical Officer
Dr. Gary Romano M.D., Ph.D.
Senior Director of Corporate Communication & Investor Relations
Ms. Katie Hogan
General Counsel
Ms. Danielle Pasqualone J.D., Ph.D.
Show More
Chief People Officer
Ms. Clare Hunt M.B.A.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Ms. Kristina Cutter M.P.H.
Chief of Staff & Head of Strategy
Ms. Virginia DeJesus-Rueff M.B.A.
Senior Vice President of Portfolio & Program Management
Ms. Norah Conway
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALEC stock?

The intrinsic value of one ALEC stock under the Base Case scenario is 6.06 USD.

Is ALEC stock undervalued or overvalued?

Compared to the current market price of 5.06 USD, Alector Inc is Undervalued by 17%.

Back to Top